Literature DB >> 20978994

Global hemostasis in pregnancy: are we using thromboelastography to its full potential?

Maha Othman1, Bani J Falcón, Rezan Kadir.   

Abstract

Pregnancy is a unique situation where significant physiological changes in all maternal organ systems take place. Most of these changes return to normal after delivery. During normal pregnancy the hemostatic balance changes in the direction of hypercoagulability, thus decreasing bleeding complications at time of delivery. The pregnancy-associated hypercoagulability sets a foundation for hemostatic abnormalities during pregnancy and may be associated with pregnancy complications. Assessment of the hemostatic status in pregnancy and its complications can be critical to diagnosis and management not only within the obstetric ward but in trauma, anesthesia, and other situations. Conventional global tests such as prothrombin time and activated partial thromboplastin time cannot define this status appropriately, and full assessment requires measurements of several parameters. Thromboelastography (TEG) is a global hemostatic test that can analyze both coagulation and fibrinolysis. The technique has been available since the 1940s, but only recently has it shown great impact within the clinical practice arena. TEG measures the interactive dynamic coagulation process from the initial fibrin formation to platelet interaction and clot strengthening to fibrinolysis, which makes it superior to other conventional tests. In addition, TEG can guide therapy by documenting changes in coagulation in vitro before a therapy is instituted and also by helping the clinician make critical decisions. Despite the clear value as a test for monitoring hemostatic status of pregnancy-related complications, TEG is still underused for reasons such as poor awareness regarding the technique and interpretations, lack of full standardization, and the unavailability of large clinical studies. However, the fact remains that TEG is undoubtedly attractive to both researchers and clinicians, particularly in a point-of-care setting. We hope that much more investment is directed to TEG studies in both experimental and clinical fields to improve applications and promote use, especially with respect to clinical decision making in pregnancy-related complications. © Thieme Medical Publishers.

Entities:  

Mesh:

Year:  2010        PMID: 20978994     DOI: 10.1055/s-0030-1265290

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

1.  CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer.

Authors:  W Jiao; J Zhao; M Wang; Y Wang; Y Luo; Y Zhao; D Tang; Y Shen
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

2.  Role of Thromboelastography Versus Coagulation Screen as a Safety Predictor in Pre-eclampsia/Eclampsia Patients Undergoing Lower-Segment Caesarean Section in Regional Anaesthesia.

Authors:  Asrar Ahmad; Monica Kohli; Anita Malik; Megha Kohli; Jaishri Bogra; Haider Abbas; Rajni Gupta; B B Kushwaha
Journal:  J Obstet Gynaecol India       Date:  2016-06-22

3.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.

Authors:  Elena N Lipets; Fazoil I Ataullakhanov
Journal:  Thromb J       Date:  2015-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.